About 200 reports

REV PRESS., ##(##), PP. ##-##.

  • Health Services
  • Demand
  • Forecast
  • Pfizer Inc.
  • Sanofi S.A.
  • PHYSICAL THERAPY

BMJ SPECIALIST JOURNALS, ##(SUPPL ##), P.

  • Health Services
  • United States
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • BARICITINIB - DRUG PROFILE

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Health Services
  • Renal Cancer
  • Stroke
  • Therapy
  • Incyte Corporation

In November 2012, Eli Lilly and Company registered a Phase III study of baricitinib, RA-BUILD to evaluate the efficacy and safety of baricitinib in Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least ## conventional disease-modifying

  • Health Services
  • Stroke
  • United States
  • Product Initiative
  • Galapagos NV

SAN-## acts as an inhibitor of very late antigen ## (VLA-## or integrin alpha ## beta ##).

  • Autoimmune Disease
  • Health Services
  • United States
  • Product Initiative
  • Pliant Therapeutics, Inc.
  • and neck, pancreatic cancer, glioblastoma, renal cell carcinoma and ovarian cancer.

One cycle lasts ## days.

  • Health Services
  • Renal Cancer
  • Therapy
  • United States
  • Product Initiative

This is the first company-sponsored trial studying patients who had not previously received an oral disease-modifying antirheumatic drug (DMARD).

  • Autoimmune Disease
  • Health Services
  • Renal Cancer
  • Stroke
  • Celgene Corporation

One such project, led by Dr.

  • Health Services
  • Neurological Disorder
  • Renal Cancer
  • Stroke
  • UCB S.A.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Health Services
  • Renal Cancer
  • Stroke
  • Therapy
  • Incyte Corporation

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Health Services
  • Hospital
  • Immunotherapy
  • Stroke
  • TaiwanJ Pharmaceuticals Co., Ltd.

Glucagon-like peptide-##, commonly known as GLP-##, is a hormone produced by the proglucagon gene in the L-cells of the gut.

  • Arthritis
  • Health Services
  • Stroke
  • United States
  • Amgen Inc.

Plan Details ##.

  • Health Services
  • Ophthalmology
  • Renal Cancer
  • Japan
  • Santen Pharmaceutical Co., Ltd.
  • SARILUMAB - DRUG PROFILE
  • AND PROGRESSIVE RA NOT PREVIOUSLY TREATED WITH MTX OR OTHER DMARDS.

Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

  • Biosimilar
  • Health Services
  • United States
  • Company Operations
  • Product Initiative

ACTEMRA IS INDICATED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO ONE OR MORE DISEASE MODIFYING ANTI-RHEUMATIC DRUGS VIA INTRAVENOUS AND SUBCUTANEOUS ROUTE.

  • Endocrine Disease
  • Health Services
  • Renal Cancer
  • United States
  • Alnylam Pharmaceuticals, Inc.
  • UK SURGICAL SUTURE MARKET REVENUE AND FORECASTS TO 2025, BY APPLICATION (US$ MN)

TABLE ##. ##.

  • Health Services
  • Stroke
  • Europe
  • Forecast
  • Market Size

A total of ## subjects between the ages of ## and ## with distance corrected near visual acuity (DCNVA) worse than ##/ ## and best corrected distance visual acuity (BCDVA) of ##/ ## or better in each eye were randomized ##:## to receive one drop of EV## (n=##) or placebo (n=##

  • Health Services
  • United States
  • World
  • Product Initiative
  • Allergan plc

ELSEVIER; ##-##.

  • Health Services
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Pfizer Inc.
  • Remicade group
  • Immunology Pipeline, Number of Products and Pipeline Growth by Indication, Q1
  • 3.4.4 Immunology

The effectiveness of the drug is such that it covered ##% of the global anti-rheumatic products market, posing a challenge to the new pipeline products in this indication.

  • Health Services
  • Pharmaceutical
  • Therapy
  • Company
  • Market Size

ACTEMRA IS INDICATED FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE TO ONE OR MORE DISEASE MODIFYING ANTI-RHEUMATIC DRUGS VIA INTRAVENOUS AND SUBCUTANEOUS ROUTE.

  • Endocrine Disease
  • Health Services
  • Monoclonal Antibody
  • Renal Cancer
  • Alnylam Pharmaceuticals, Inc.

ET Presenter: Jessica Ailani Location: Room ## in Hall A Date: Saturday, July ##, 2019 Time: ##:##p. m. - ##:##p. m.

  • Health Services
  • Heart Failure
  • Stroke
  • United States
  • LivaNova PLC

This is the first company-sponsored trial studying patients who had not previously received an oral disease-modifying antirheumatic drug (DMARD).

  • Health Services
  • Pharmaceutical
  • Stroke
  • United States
  • Product Initiative

The molecules developed by Companies in Phase III, Phase II and Phase I stages are ##, ## and ## respectively.

  • Health Services
  • Pharmaceutical
  • Stroke
  • Therapy
  • United States
  • IMMUNOLOGY THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR STELARA, 2017
  • IMMUNOLOGY THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR RITUXAN, 2017

How antirheumatic drugs protect joints from damage in rheumatoid arthritis.

  • Health Services
  • Stroke
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

The prominent features of this report are - ##.

  • Health Services
  • Pharmaceutical
  • Renal Cancer
  • World
  • Novartis AG
  • Major Product Offerings
  • TROGE MEDICAL

Additionally, one in eight men and one in eleven women are likely to die from this disease.

  • Health Services
  • Renal Cancer
  • Stroke
  • World
  • Market Size

The prominent features of this report are - ##.

  • Drug Development
  • Health Services
  • Stroke
  • World
  • Otsuka Pharmaceutical Co., Ltd.

TABLE ##. ##.

  • Health Services
  • Medical Textile
  • Central America
  • Forecast
  • Market Size

The drug candidate is a chromene coxib analog.

  • Health Services
  • Pharmaceutical
  • Stroke
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Drug Development
  • Health Services
  • Stroke
  • World
  • Otsuka Pharmaceutical Co., Ltd.

SANTEN IS A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY BASED IN JAPAN THAT FOCUSES ON THE OPHTHALMIC AND ANTI-RHEUMATIC SECTORS.

  • Health Services
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.